Adjuvant nivolumab plus ipilimumab vs placebo for localised renal cell carcinoma at high risk of relapse after nephrectomy

Bookmark and Share
Published: 11 Sep 2022
Views: 41
Rating:
Save
Dr Robert Motzer, Memorial Sloan Kettering Cancer Center, New York, USA

Dr Robert Motzer presents his study of the results from the randomised, phase 3 CheckMate 914 trial. The study explores adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localised renal cell carcinoma (RCC) at high risk of relapse after nephrectomy. 

CheckMate 914 key inclusion criteria included: radical or partial nephrectomy with negative surgical margins > 4 and ≤ 12 weeks before randomisation.

The results demonstrated that patients with localised RCC at high risk of relapse after nephrectomy did not meet the primary endpoint of DFS.